🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

482 results for “60” Clear

  1. Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1,200 mg concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  2. LEE011, LEE011, LTT462, LXH254, LXH254, TMT212, LXH254, LTT462, LXH254

    Novartis Pharmaceuticals

    Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

    phase 2 small molecule active

    1 trial

  3. Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, IMBRUVICA 140 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 15 mg hard capsules, JNJ-54179060, Lenalidomide Accord 2.5 mg hard capsules, Ruxi

    Janssen-Cilag International N.V.

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  4. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.

    phase 2 small molecule active

    1 trial

  5. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  6. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  7. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, ART6043, ART6043, ART6043, ART6043, ART6043

    Lacuna Pharma Pty Ltd

    Metastatic solid tumors, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  8. LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas

    phase 2 small molecule active

    1 trial

  9. MEDI0618, Placebo to match MEDI0618

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 2 small molecule active

    1 trial

  10. MEDI8968 600 mg IV, 300 mg SC

    MedImmune

    Chronic Obstructive Pulmonary Disease

    phase 2 mab completed

    1 trial

  11. MK-2060, Placebo to MK-2060

    Merck Sharp and Dohme

    Prevention of arteriovenous graft thrombosis

    phase 2 small molecule active

    1 trial

  12. Mecasermin rinfabate

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lung Disease

    phase 2 small molecule active

    1 trial

  13. Mektovi 15 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)

    phase 2 small molecule active

    1 trial

  14. Metronidazole 500 mg / 100 ml Intravenous Infusion, Metronidazole 500mg/100ml Solution for Infusion, Aztreonam and Avibactam (1.5g/0.5g) Powder for Concentrate for Solution for Infusion, Metronidazole

    Pfizer Australia Pty Ltd

    Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection

    phase 2 small molecule active

    1 trial

  15. NNC6019-0001

    Novo Nordisk A/S

    Transthyretin Amyloid Cardiomyopathy (ATTR CM)

    phase 2 small molecule completed

    1 trial

  16. NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Disc Medicine

    metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  17. Nivolumab Subcutaneous, BMS986482, FDC Nivolumab + Relatlimab + rHuPH20 Injection, BMS986482, BEVACIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  18. OPDIVO 10 mg/mL concentrate for solution for infusion., Mektovi 15 mg film-coated tablets, YERVOY 5 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF V600 mutation–positive unresectable or metastatic melanoma

    phase 2 small molecule active

    1 trial

  19. OXALIPLATIN, IRINOTECAN, Vectibix 20 mg/ml concentrate for solution for infusion, FOLINIC ACID, CALCIUM LEVOFOLINATE, FLUOROURACIL

    Ningbo Cancer Hospital

    RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method

    phase 2 small molecule active

    1 trial

  20. PEMBROLIZUMAB

    Pari Pharma GmbH

    Kaposi's sarcoma

    phase 2 small molecule active

    1 trial

  21. PKN605, Placebo to PKN605 50 mg film-coated tablets

    Novartis Pharmaceuticals

    Atrial Fibrillation

    phase 2 small molecule active

    1 trial

  22. PTC857, Placebo to match PTC857 60 mg/mL oral solution, Utreloxastat 62.5

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  23. Phase I/II First-In-Human open-label trial to assess safety and efficacy of STX-241 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    Pierre Fabre Medicament

    locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    phase 2 other active

    1 trial

  24. Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    type 2 diabetes

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources